UK markets open in 4 hours 11 minutes
  • NIKKEI 225

    28,471.45
    +652.12 (+2.34%)
     
  • HANG SENG

    20,071.87
    -10.56 (-0.05%)
     
  • CRUDE OIL

    93.88
    -0.46 (-0.49%)
     
  • GOLD FUTURES

    1,802.90
    -4.30 (-0.24%)
     
  • DOW

    33,336.67
    +27.16 (+0.08%)
     
  • BTC-GBP

    19,666.23
    -334.14 (-1.67%)
     
  • CMC Crypto 200

    569.13
    -5.61 (-0.98%)
     
  • ^IXIC

    12,779.91
    -74.89 (-0.58%)
     
  • ^FTAS

    4,131.26
    -19.42 (-0.47%)
     

Liposomal Drug Delivery Devices Global Market Report 2022: Johnson and Johnson, Novartis & Gilead Sciences Among Key Players Driving 10.3% Annual Growth

·4-min read
Company Logo
Company Logo

Dublin, Aug. 01, 2022 (GLOBE NEWSWIRE) -- The "Liposomal Drug Delivery Devices Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

The global liposomal drug delivery devices market is expected to grow from $3.72 billion in 2021 to $4.10 billion in 2022 at a compound annual growth rate (CAGR) of 10.3%. The market is expected to grow to $6.03 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%.

North America was the largest region in the liposomal drug delivery devices market in 2021. Asia Pacific was the second-largest region in the liposomal drug delivery devices market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the liposomal drug delivery devices market during the forecast period. Liposomal drug delivery systems are used as targeted therapy for cancer treatment in radiation therapy, chemotherapy, and surgical resection. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the liposomal drug delivery devices market over the forthcoming years.

The high cost of liposomal drug delivery devices is expected to limit the growth of the market during the forecast period. The high cost of devices makes liposomal treatment more expensive and unaffordable for patients, thereby hindering the growth of the market. For instance, according to the Journal of Biotechnology & Biomaterials, lipid/liposomal drug delivery systems are expensive to produce attributing to their high production cost.

The high cost of products results from the high cost associated with the raw materials used in lipid excipients and the requirement of expensive equipment to increase manufacturing. Furthermore, according to the ScienceDirect Journal, liposomal drug delivery is the most expensive treatment for topical disorders such as psoriasis, atopic dermatitis, and skin cancer.
Several big companies are undertaking various strategic initiatives such as collaborations and new product development, which is likely to become a major trend in the liposomal drug delivery devices market. Various companies are coming together to develop liposomal drug delivery systems to expand their product portfolio and operations worldwide.

Scope
Markets Covered:

1) By Type: Liposomal Doxorubicin; Liposomal Paclitaxel; Liposomal Amphotericin B; Other Types
2) By Application: Fungal Diseases; Cancer Therapy; Pain Management; Viral Vaccines; Photodynamic Therapy
3) By End User: Hospitals; Diagnostic Centers; Ambulatory Surgery Centers/Clinics; Other End Users

Key Topics Covered:

1. Executive Summary

2. Liposomal Drug Delivery Devices Market Characteristics

3. Liposomal Drug Delivery Devices Market Trends And Strategies

4. Impact Of COVID-19 On Liposomal Drug Delivery Devices

5. Liposomal Drug Delivery Devices Market Size And Growth

6. Liposomal Drug Delivery Devices Market Segmentation

7. Liposomal Drug Delivery Devices Market Regional And Country Analysis

8. Asia-Pacific Liposomal Drug Delivery Devices Market

9. China Liposomal Drug Delivery Devices Market

10. India Liposomal Drug Delivery Devices Market

11. Japan Liposomal Drug Delivery Devices Market

12. Australia Liposomal Drug Delivery Devices Market

13. Indonesia Liposomal Drug Delivery Devices Market

14. South Korea Liposomal Drug Delivery Devices Market

15. Western Europe Liposomal Drug Delivery Devices Market

16. UK Liposomal Drug Delivery Devices Market

17. Germany Liposomal Drug Delivery Devices Market

18. France Liposomal Drug Delivery Devices Market

19. Eastern Europe Liposomal Drug Delivery Devices Market

20. Russia Liposomal Drug Delivery Devices Market

21. North America Liposomal Drug Delivery Devices Market

22. USA Liposomal Drug Delivery Devices Market

23. South America Liposomal Drug Delivery Devices Market

24. Brazil Liposomal Drug Delivery Devices Market

25. Middle East Liposomal Drug Delivery Devices Market

26. Africa Liposomal Drug Delivery Devices Market

27. Liposomal Drug Delivery Devices Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The Liposomal Drug Delivery Devices Market

29. Liposomal Drug Delivery Devices Market Future Outlook and Potential Analysis

30. Appendix

Companies Mentioned

  • Fudan-Zhangjiang

  • Pacira

  • Johnson and Johnson

  • Gilead Sciences

  • Novartis

  • Luye Pharma

  • CSPC

  • Ipsen (Onivyde)

  • Teva Pharmaceutical

  • Sigma-Tau Group

  • Sun Pharmaceutical

  • T&T Scientific Corporation

For more information about this report visit https://www.researchandmarkets.com/r/m3tg3t

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting